Novavax | NVAX - Operating Expenses


Novavax reported $126.2M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Adma Biologics USD 64.2M 12.21M Mar/2026
Agenus USD -199.08M 22.15M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Cassava Sciences USD 11.17M 2.38M Mar/2026
Geron USD 52.07M 6.73M Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 960M 817M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026